a year ago
SRPT
AnalystsGil BlumGil Blum's Stock Forecasts
AnalystsGil Blum
Sectors:
Industries:
Analyst Ranking
Top 2%
#96 out of 5267 analysts
Average Return
+16.78%
Win Rate
42%201 out of 479
Risk vs Reward
Poor
Good
Gil Blum's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Celcuity IncCELC | +1,278.14% | $10.52 | $144.98 | 2025-05-15 - 2026-05-04 | Buy |
Celcuity IncCELC | +1,169.12% | $9.23 | $117.14 | 2025-04-11 - 2026-04-10 | Buy |
Celcuity IncCELC | +1,128.63% | $9.29 | $114.14 | 2025-04-01 - 2026-03-31 | Buy |
Celcuity IncCELC | +985.99% | $13.35 | $144.98 | 2025-06-30 - 2026-05-04 | Buy |
Celcuity IncCELC | +728.28% | $12.59 | $104.28 | 2025-02-06 - 2026-02-05 | Buy |
Gil Blum Analyst Color
Get additional color on Gil Blum's coverage of popular stocks
2 years ago
AUTL
2 years ago
AUTL
Gil Blum's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Artiva Biotherapeutics IncARTV | 9 | Buy | $18.00 | +59.43% | Reiterates | a day ago |
Celcuity IncCELC | 25 | Buy | $157.00 | +8.29% | Maintains | a day ago |
Nurix Therapeutics IncNRIX | 31 | Buy | $26.00 | +53.57% | Reiterates | 12 days ago |
Lyell Immunopharma IncLYEL | 1 | Buy | $44.00 | +112.36% | Initiates Coverage On | 25 days ago |
Autolus Therapeutics PLCAUTL | 36 | Buy | $10.00 | +536.94% | Reiterates | a month ago |
Absci CorpABSI | 10 | Buy | $7.00 | +24.56% | Reiterates | a month ago |
Nkarta IncNKTX | 18 | Buy | $11.00 | +264.24% | Maintains | a month ago |
Solid Biosciences IncSLDB | 4 | Buy | $19.00 | +162.79% | Reiterates | 2 months ago |
Taysha Gene Therapies IncTSHA | 33 | Buy | $12.00 | +80.72% | Maintains | 2 months ago |
Cartesian Therapeutics IncRNAC | 25 | Buy | $42.00 | +506.06% | Reiterates | 2 months ago |
Immunocore Holdings PLCIMCR | 15 | Buy | $75.00 | +162.97% | Maintains | 2 months ago |
Recursion Pharmaceuticals IncRXRX | 26 | Buy | $8.00 | +127.27% | Reiterates | 2 months ago |
Crispr Therapeutics AgCRSP | 28 | Buy | $82.00 | +53.04% | Maintains | 3 months ago |
Arcellx IncACLX | 24 | Buy | $105.00 | -8.75% | Reiterates | 3 months ago |
Mereo Biopharma Group PLCMREO | 21 | Buy | $3.00 | +945.30% | Maintains | 4 months ago |
Geron CorpGERN | 23 | Buy | $4.00 | +154.78% | Maintains | 6 months ago |
Tscan Therapeutics IncTCRX | 8 | Buy | $6.00 | +391.80% | Maintains | 6 months ago |
Amicus Therapeutics IncFOLD | 2 | Buy | $14.00 | -3.38% | Upgrades | 8 months ago |
Novabridge BiosciencesNBP | 17 | Buy | $6.00 | +150.00% | Reiterates | 8 months ago |
Generation Bio CoGBIO | 18 | Buy | $15.00 | +180.90% | Reiterates | 9 months ago |
Sarepta Therapeutics IncSRPT | 33 | Hold | $50.00 | +126.86% | Downgrades | 10 months ago |
Rocket Pharmaceuticals IncRCKT | 21 | Hold | $42.00 | +1,063.43% | Downgrades | a year ago |
Shattuck Labs IncSTTK | 13 | Hold | $8.00 | N/A | Downgrades | 2 years ago |
Nextcure IncNXTC | 9 | Buy | $48.00 | N/A | Reiterates | 2 years ago |
G1 Therapeutics IncGTHX | 17 | Buy | $6.00 | N/A | Maintains | 2 years ago |
Gamida Cell LtdGMDAQ | 8 | Buy | $6.00 | N/A | Reiterates | 2 years ago |
Cti Biopharma CorpCTIC | 5 | Buy | $9.00 | N/A | Reiterates | 3 years ago |
Tectonic Therapeutic IncTECX | 4 | Buy | $72.00 | N/A | Reiterates | 3 years ago |
Fate Therapeutics IncFATE | 1 | Hold | N/A | N/A | Initiates Coverage On | 4 years ago |
Spyre Therapeutics IncSYRE | 1 | Buy | $225.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.